WATERTOWN, Mass.--(BUSINESS WIRE)--Sep. 8, 2020--
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that members of its management team will participate virtually in the following upcoming conferences:
H.C. Wainwright 22nd Annual Global Investment Conference
Date: Monday, September 14, 2020
Presentation Time: 1:00 p.m. ET
2020 Cantor Global Healthcare Conference
Date: Tuesday, September 15, 2020
Presentation Time: 10:40 a.m. ET
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Monday, September 21, 2020
Fireside Chat Time: 2:30 p.m. ET
To access a live webcast and subsequent archived recording of each presentation, please visit “Events” in the “Investors” section of the Kala website at http://kalarx.com.
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus penetrating particle Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the January 2019 launch of INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% and its investigational product candidate, EYSUVISTM (loteprednol etabonate ophthalmic suspension) 0.25%, for which a New Drug Application (NDA) is under review by the United States Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) goal date set for October 30, 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200908005028/en/
Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200
Source: Kala Pharmaceuticals, Inc.